Ki67 Assessment in Breast Cancer: Are We There yet?
Cet article présente les recommandations issues d'une conférence internationale de consensus sur la validité et l'utilité clinique de l'analyse immunohistochimique de l'antigène Ki-67 chez les patientes atteintes d'un cancer du sein
2Breast cancer is a heterogeneous disease, comprised of multiple entities with distinct risk factors, clinical behaviors, molecular profiles,and responsesto therapy. Over the last 20 years, it has become evident that estrogen receptor (ER)-positive and ER-negative breast cancers are fundamentally different diseases, and that proliferation assessment is an independent prognostic marker for patients with ER-positive breast cancers[1]. In fact, the prognostic value of several multi-parameter gene expression assays (i.e. prognostic gene signatures)currently used in clinical practice for the management of patients with early stage ER-positive disease is largelydetermined by the expression levels of proliferation-related genes[1-5]. Consistent with this notion, proliferation has also been shown to be the major distinction between the two luminal ‘intrinsic gene’ subtypes of ER-positive disease, namely Luminal A and Luminal B[1-4].
Journal of the National Cancer Institute , éditorial en libre accès, 2019